DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 Fourth Quarte ...

- Purchase commitment is for a minimum of $1.475 million of Symvess product -DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase commitment of $1.475 million of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals within the King ...

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis The offering was led by a new life science dedicated investor and a long-only mutual fund DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commerci ...

Product Approval and Market Launch - Humacyte's Symvess® (ATEV) received FDA approval in December 2024 for treating extremity vascular trauma, with a market launch expected in 2025[9]. - The company has established commercial-scale manufacturing with an annual capacity of up to 40,000 ATEVs[9]. - The current price point for Symvess is $17,000, making it the second most cost-effective option after saphenous vein grafts, resulting in a net cost reduction of $104,573[49]. - The anticipated milestones for 2026 include the U.S. commercial launch of CABG (CTEV) and the publication of Phase 3 results for the V007 dialysis study[137]. Clinical Performance and Safety - In clinical studies, Symvess demonstrated a primary patency rate of 87.1% and a secondary patency rate of 91.5%, compared to 78.9% for synthetic grafts[36]. - The conduit infection rate for Symvess was 0.9%, significantly lower than the 8.4% rate for synthetic grafts[36]. - The amputation rate for patients using Symvess was 4.5%, compared to 24.3% for synthetic grafts[36]. - ATEV demonstrated a functional patency of 81.3% at 6 months compared to 66.4% for autogenous fistula (AVF), indicating superior performance[60]. - In the V007 trial, ATEV showed a secondary patency rate of 68.3% at 12 months, outperforming AVF at 62.2%[60]. - ATEV has shown no increased safety events per year of usability in the expected target population, with treatment emergent adverse events at 96.3% for ATEV compared to 98.2% for AVF[64]. - The ATEV was successfully used in a 70-year-old patient with severe vascular disease, showing a patent ATEV without significant stenosis at the distal anastomosis after one year[88]. Strategic Partnerships and Market Focus - The company has a strategic partnership with Fresenius Medical Care Holdings, Inc. for marketing and distribution of its 6 millimeter ATEV in specified markets[1]. - Humacyte's technology aims to address major drawbacks of current treatment options for vascular injuries, providing a definitive and permanent repair solution[35]. - The company is focused on expanding its product offerings through its bioengineering platform, which enables the development of a broad range of regenerative medicine products[11]. - The company is focused on addressing unmet needs in multiple markets, including vascular trauma and peripheral arterial disease, through its bioengineering platform[139]. Financial Impact and Market Potential - Symvess is associated with a potential savings of $40,705 per patient compared to synthetic grafts, with infection charges per synthetic graft at $8,848 versus $589,921 for vascular graft infections[47]. - The total addressable market (TAM) for Symvess in the U.S. vascular trauma market is estimated at 26,000 patients, with 18,667 being emergent vascular trauma cases[42]. Future Developments and Innovations - Humacyte's pipeline includes multiple potential commercial launches, with ongoing Phase 3 trials for various applications[17]. - The company plans to launch the Coronary Tissue Engineered Vessel (CTEV) for Coronary Artery Bypass Grafting (CABG) in the U.S. and expand into international markets[134]. - The BioVascular Pancreas (BVP) demonstrated a 100% cure rate for diabetes in a rat model, with all animals showing normalized blood glucose levels[123]. - Over 80% islet retention was observed at 2 months in non-human primate studies, indicating superior islet survival compared to existing transplantation methods[125]. - The BVP is designed to deliver pancreatic islets while promoting neovascularization and long-term islet survival, addressing significant drawbacks of current islet transplantation methods[108]. - The company operates 8 LUNA200 systems, with an annual capacity expected to exceed 40,000 ATEVs, supporting commercial manufacturing scale[135]. - The CTEV showed positive patency results in animal models, with no significant stenosis or adverse events reported during the study duration[104]. Demographic Insights - The analysis of hemodialysis patients indicates that women have a 90% increased risk of complications with AVG ± CVC access compared to men, highlighting a significant unmet need in this demographic[57]. - The V012 trial aims to compare ATEV to AVF in female patients, with a target enrollment of 150 subjects and an interim analysis planned after 80 patients[70]. Military Applications - The Department of Defense (DoD) has designated Symvess as a "Priority Product," with funding for its development and evaluation in battlefield injuries, achieving a 100% limb salvage rate in Ukrainian warfighters[51].

Core Insights - Humacyte has submitted a Marketing Authorization Application (MAA) for its acellular tissue engineered vessel, Symvess, to the Israel Ministry of Health for arterial trauma repair, with plans for hospital-by-hospital availability prior to approval [1][2] - The company is preparing for global expansion of Symvess, leveraging FDA approval and clinical results to expedite commercialization in multiple countries, including the Middle East [2] Company Overview - Humacyte, Inc. is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [1][12] - The company aims to transform medical practices by delivering advanced tissue constructs and organ systems to improve patient outcomes [12] Product Details - Symvess is designed for urgent revascularization in adults with extremity arterial injuries when autologous vein grafts are not feasible, providing an off-the-shelf solution that saves critical surgical time [2][4] - Clinical trials have shown Symvess to have low infection rates and high limb salvage rates, with a notable humanitarian program in Ukraine demonstrating 100% survival and zero amputations among treated patients [2] Regulatory Status - The FDA approved Humacyte's Biologics License Application for Symvess in December 2024, and the product is currently in late-stage clinical trials for other vascular applications [12] - Symvess is still considered investigational for uses beyond FDA approval in extremity vascular trauma [3] Safety Information - Important safety information includes risks of graft failure, thrombosis, and potential transmission of infectious diseases, with common adverse reactions being vascular graft thrombosis, fever, and pain [5][9][11]

Core Insights - The discussion highlights the evolution of a company's technology and its recent product launches in the vascular trauma sector, indicating a positive trajectory in clinical success and market engagement [1] Group 1: Product Launch and Market Engagement - The company successfully launched products targeting vascular trauma, dialysis, and CABG (coronary artery bypass grafting) over the past year, generating excitement and demonstrating clinical success [1] - There have been learnings and course corrections made during the year, suggesting an adaptive approach to market challenges and product development [1] Group 2: Future Outlook - The company is preparing to enter 2026 with insights gained from previous experiences, indicating a focus on continuous improvement and strategic planning for future growth [1]

Humacyte FY Conference Summary Company Overview - **Company**: Humacyte (NasdaqGS:HUMA) - **Industry**: Biotechnology, specifically in the field of bioengineered vascular conduits Key Points and Arguments Product Launch and Market Entry - Humacyte launched its first-in-class product into the market in 2025, focusing on vascular trauma, dialysis, and CABG (coronary artery bypass grafting) [9][10] - The company experienced a learning curve regarding the time required for approval from Value Analysis Committees (VAC), which is longer than anticipated due to post-COVID spending consciousness in hospitals [9][10] - The current Average Selling Price (ASP) of the product is approximately $17,000-$20,000, with adjustments made to facilitate administrative processes in hospitals [10] Clinical and Economic Validation - Humacyte has achieved a VAC approval rating of over 70%, indicating strong clinical and health economic arguments for its product [9][10] - Publications in 2025 demonstrated that even at higher price points, the product saves money for trauma centers by avoiding amputations and infections [22] - The product's outcomes in patients without available veins are comparable to traditional vein treatments, enhancing its value proposition [23] Focus on Education and Training - The company is increasing its focus on educating surgeons and hospital staff about the new product, as many surgeons have never used a new conduit in their careers [11] - A growing medical science liaison team is being established to support this educational effort [11] Upcoming Trials and Regulatory Engagement - A Phase 3 trial comparing Humacyte's vessel to the gold standard fistula for dialysis access has shown positive 1- and 2-year data, with plans to publish results soon [24][25] - An interim read on a second trial focusing on women is expected in a few months, which could lead to a supplemental Biologics License Application (BLA) later in 2026 [25][32] Strategic Partnerships - Humacyte has a significant relationship with Fresenius, the largest provider of renal care services globally, which supports both financial and collaborative efforts [34][36] - Fresenius holds distribution rights for Humacyte's product outside the U.S., while Humacyte retains distribution rights within the U.S. [36] Market Dynamics and Future Outlook - The trauma market is concentrated with about 200 Level I Trauma Centers in the U.S., allowing for effective coverage with a small sales force [59] - The dialysis market is expected to be at least three times the size of the trauma market, providing significant revenue potential [59] - R&D costs are expected to decrease as clinical trials wind down, while sales are anticipated to ramp up, particularly in the trauma and dialysis markets [60] Financial Projections - The company expects to see an increase in sales as it expands its commercial team for dialysis, while R&D costs will continue to decline [60] Additional Important Insights - The product addresses a critical need for patients who struggle with traditional dialysis access methods, particularly women, who experience higher failure rates with fistulas [26][27] - The company is actively engaging with CMS to secure favorable reimbursement terms, aiming for a pass-through reimbursement at ASP plus six [33] This summary encapsulates the key discussions and insights from Humacyte's FY conference, highlighting the company's strategic direction, product validation, and market opportunities.

Company Overview - Humacyte is a company focused on regenerative medicine technology, with a strong emphasis on innovative solutions in the medical devices sector [2]. Leadership - The conference featured key executives from Humacyte, including CEO, President, and Founder Dr. Laura Niklason, and CFO Dale Sanders, highlighting the leadership team's involvement in the company's strategic direction [2]. Conference Participation - Humacyte has been a multiyear participant in the conference, indicating its ongoing commitment to engaging with the medical research community and showcasing its advancements [1].

Humacyte Conference Call Summary Company Overview - **Company**: Humacyte - **Industry**: Regenerative Medicine, Medical Devices - **Technology**: Engineered tissue platform for creating functional implantable human tissues at commercial scale, specifically engineered blood vessels Key Points and Arguments 1. **Product Development and Approval**: Humacyte received FDA approval for its first engineered blood vessel, SYMVESS, which is 40 centimeters long and 6 millimeters in diameter, with a market launch in Q1 2025 [3][4] 2. **Clinical Experience**: Over 700 patients have been treated with Humacyte's technology, with no instances of immune rejection reported [3] 3. **Manufacturing**: The company operates a vertically integrated manufacturing platform, allowing for quality control and stability [4] 4. **Partnerships**: Significant partnerships include collaborations with Fresenius Medical Care and the Department of Defense [4] 5. **Value Proposition in Trauma**: SYMVESS offers a low infection rate of 0.9%, significantly lower than the 9% infection rate of traditional plastic grafts, and a 4% amputation rate compared to nearly 25% for synthetic grafts [13][14] 6. **Clinical Data**: The clinical data supporting the approval of SYMVESS showed better patency rates and lower infection and amputation rates compared to traditional methods [12][14] 7. **Dialysis Indication**: Humacyte is studying the use of SYMVESS for hemodialysis access, with a Phase III study showing better function at 6 and 12 months compared to the gold standard fistula [27] 8. **Female Patient Focus**: The company is conducting a trial specifically for female dialysis patients, who often experience higher failure rates with fistulas [29] 9. **Pipeline Expansion**: Plans to develop smaller caliber versions of the technology for coronary artery bypass grafting (CABG) are underway, with trials expected to start in Q3 2025 [38][39] 10. **Economic Argument**: Although SYMVESS costs between $17,000-$20,000, the overall cost to hospitals is lower due to reduced complications and shorter operating room times compared to traditional methods [20][68] Additional Important Content 1. **Durability and Living Tissue**: The engineered vessels become living arteries over time, repopulated by the patient's own cells, enhancing durability and resistance to infection [16] 2. **Long-term Data**: Long-term studies show stable patency and limb salvage rates, with an infection-free rate of approximately 98% [18] 3. **Comparative Analysis**: Retrospective comparisons with the PROOVIT Database indicate that SYMVESS performs comparably to vein grafts in terms of patency and complications [19] 4. **Regulatory Milestones**: The company has met all major milestones for 2025 and anticipates significant developments in 2026 [38] This summary encapsulates the key insights from the Humacyte conference call, highlighting the company's innovative technology, clinical efficacy, and strategic direction in the regenerative medicine industry.

Core Insights - Humacyte, Inc. is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at a commercial scale [2] Company Overview - Humacyte is developing acellular tissues to treat a variety of diseases, injuries, and chronic conditions [2] - The company received FDA approval for its acellular tissue engineered vessel (ATEV), Symvess, for vascular trauma in December 2024 [2] - ATEVs are in late-stage clinical trials for other vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [2] - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and other novel cell and tissue applications [2] - The 6mm ATEV for AV access in hemodialysis was the first to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and also holds Fast Track designation [2] - The ATEV has received priority designation for vascular trauma treatment from the U.S. Secretary of Defense [2] Upcoming Events - Humacyte's management will participate in the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, from 10:30-11:00 am Eastern Time [2] - The company will also participate in the Barclays 28th Annual Global Healthcare Conference with a fireside chat scheduled from 1:00-1:25 pm Eastern Time [2]